Amachiza amatsha okugula okushukumayo

Ngo-Meyi 15, i-Vanda Pharmaceuticals, inkampani yase-US ye-biopharmaceutical, yazisa ukuba isifundo sesibini seSigaba sesi-III seyeza elitsha le-Tradipitant (tradipitant) yonyango lwe-motion disease (ingakumbi ukugula okuhambayo) lufumene iziphumo ezilungileyo.
I-Tradipitant yi-neurokinin-1 (NK1) ye-receptor antagonist eyenziwe ngu-Eli Lilly. I-Vanda ifumene amalungelo ophuhliso lwehlabathi jikelele lweTradipitant ngelayisenisi ngo-Ephreli 2012.
Okwangoku, uVanda uphuhlise iTradipitant yezalathisi ezinje nge-atopic dermatitis pruritus, gastroparesis, usulelo olutsha lwe-coronavirus, ukugula okushukumayo, ukuba likhoboka lotywala, i-social phobia, kunye nokuqunjelwa.
Olu pho nonongo lweSigaba se-3 lubandakanya izigulane ze-316 zesifo sokunyakaza kunye nembali yesifo sokunyakaza, esaphathwa nge-170 mg Tradipitant, 85 mg Tradipitant, okanye i-placebo ngexesha lohambo lomkhumbi.
Bonke abathathi-nxaxheba babenembali yokuguliswa lulwandle. Isiphelo sokuqala sophononongo sasisiphumo se-tradipitant (170 mg) ekugabheni. Iimpawu eziphambili zesibini zezi: (1) umphumo we-tradipitant (85 mg) ekugabheni; (2) umphumo we-tradipitant ekuthinteleni isicaphucaphu kunye nokuhlanza.
Kuxelwe ukuba isigulo sokuhamba sihlala sisisidingo sonyango esingafezekiswanga. I-US Food and Drug Administration (FDA) ayizange ivume ichiza elitsha lokunyanga ukugula okuhambayo iminyaka engaphezu kwe-40 ukususela ekubeni ivume i-scopolamine (i-patch transdermal ebekwe emva kwendlebe) kwi-1979.

Ngokusekelwe kwidatha evela kwizifundo ezimbini zeSigaba sesi-III, i-Vanda iya kungenisa isicelo sokuthengisa i-tradipitant kwi-FDA yonyango lwesifo sokunyakaza kwikota yesine ye-2024.